Keros Therapeutics (KROS) said Wednesday it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."
The decision includes all treatment arms, including the 1.5 mg/kg and placebo groups.
Keros Therapeutics halted higher dose treatments of 3.0 mg/kg and 4.5 mg/kg last December due to similar concerns.
Keros Therapeutics shares were down more than 16% in recent premarket activity.
Price: 10.39, Change: -2.09, Percent Change: -16.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.